Login

Company Executives

Officer Age In this role 2025 pay Source
Owen Hughes
Chief Executive Officer
Title from the Form 4 dated Jul 14, 2026
Not stated Not stated $1,140,207
Jeffrey Trigilio
Chief Financial Officer and Treasurer
42 Since 2026
this year
Not reported
Maricel Montano
Chief Legal Officer and Corporate Secretary
42 Since 2025
1 year
Not reported
Bradley Sitko
Chief Investment Officer
45 Since 2023
3 years
$853,495

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Mar 30, 2026 · updated by the 8-K of Jul 14, 2026

Directors
3
serving now
Director Source
Todd C. Davis Joined Jul 14, 2026
Octavio Espinoza Joined Jul 14, 2026
Andrew Reardon Joined Jul 14, 2026

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

3 disclosed in the proxy filed Mar 30, 2026
BVF
a beneficial holder of more than 5% of our Common Stock
$3.0 million
January 2026

Arranger fee of $3.0 million payable to the Company by Xeno for structuring the acquisition of Repare's common shares; BVF owned approximately 24.0% of Repare before the acquisition.

With Xeno Therapeutics, Inc. Open in proxy
BVF
a beneficial holder of more than 5% of our Common Stock
$5.9 million
October 2025

Short-term bridge loan extended by the Company to Xeno to facilitate the ESSA acquisition; repaid in October 2025. BVF owned approximately 24.7% of ESSA before the acquisition.

With Xeno Therapeutics, Inc. Open in proxy
BVF
a beneficial holder of more than 5% of our Common Stock
$3.0 million
October 2025

Arranger fee of $3.0 million paid to the Company by Xeno following the closing of the ESSA acquisition.

With Xeno Therapeutics, Inc. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support